Kempharm Historical Income Statement

KMPH -  USA Stock  

USD 10.75  0.24  2.18%

Historical analysis of Kempharm income statement accounts such as Revenues of 14.6 M can show how well Kempharm performed in making a profits. Evaluating Kempharm income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Kempharm's future profits or losses. Financial Statement Analysis is much more than just reviewing and examining Kempharm latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Kempharm is a good buy for the upcoming year.
Please see Stocks Correlation.

Search Historical Statements 


Kempharm Net Income

(13.77 Million)Share

About Kempharm Income Statement Analysis

Kempharm Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Kempharm shareholders. The income statement also shows Kempharm investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Kempharm Income Statement Chart

Kempharm Income Statement is one of the three primary financial statements used for reporting Kempharm's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Kempharm revenue and expense. Kempharm Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Kempharm Selling General and Administrative Expense is most likely to increase significantly in the upcoming years. The last year's value of Selling General and Administrative Expense was reported at 7.92 Million. The current Weighted Average Shares is estimated to increase to about 4.3 M, while Consolidated Income is projected to decrease to (13.8 M).

Earning Before Interest and Taxes EBIT

Earnings Before Interest and Tax is calculated by adding Income Tax Expense and Interest Expense back to Net Income.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Kempharm financial statement analysis. It represents the amount of money remaining after all of Kempharm operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. The portion of profit or loss for the period; net of income taxes; which is attributable to the parent after the deduction of Net Income Available to Non-controlling Interests from Consolidated Income; and before the deduction of Preferred Dividends.


Revenues refers to the total amount of money received by Kempharm for goods sold or services provided during a certain time period. It also includes all of Kempharm sales as well as any other increase in Kempharm equity.Revenues are reported on Kempharm income statement and calculated before any expenses are subtracted. Amount of Revenue recognized from goods sold; services rendered; insurance premiums; or other activities that constitute an earning process. Interest income for financial institutions is reported net of interest expense and provision for credit losses.
Most accounts from Kempharm income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Kempharm current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Please see Stocks Correlation.Kempharm Selling General and Administrative Expense is most likely to increase significantly in the upcoming years. The last year's value of Selling General and Administrative Expense was reported at 7.92 Million. The current Weighted Average Shares is estimated to increase to about 4.3 M, while Consolidated Income is projected to decrease to (13.8 M).
 2020 2021 (projected)
Interest Expense4.79 M4.75 M
Gross Profit13.29 M14.56 M

Kempharm income statement Correlations

Kempharm Account Relationship Matchups

Kempharm income statement Accounts

201620172018201920202021 (projected)
Consolidated Income(16.52 M)(43.39 M)(56.47 M)(24.52 M)(12.76 M)(13.77 M)
Earning Before Interest and Taxes EBIT(11.02 M)(37.65 M)(51.12 M)(19.69 M)(8.01 M)(8.64 M)
Earning Before Interest and Taxes USD(11.02 M)(37.65 M)(51.12 M)(19.69 M)(8.01 M)(8.64 M)
Interest Expense5.51 M5.78 M5.47 M4.86 M4.79 M4.75 M
Net Income(16.52 M)(43.39 M)(56.47 M)(24.52 M)(12.76 M)(13.77 M)
Net Income Common Stock(16.52 M)(43.39 M)(56.47 M)(24.52 M)(12.76 M)(13.77 M)
Net Income Common Stock USD(16.52 M)(43.39 M)(56.47 M)(24.52 M)(12.76 M)(13.77 M)
Operating Expenses37.48 M33.37 M55.9 M33.18 M18.9 M26.07 M
Operating Income(37.48 M)(33.37 M)(55.9 M)(20.34 M)(5.61 M)(6.05 M)
Research and Development Expense20.47 M20.59 M41.76 M19.41 M8.84 M9.08 M
Selling General and Administrative Expense14 M12.77 M12.51 M10.82 M7.92 M9.44 M
Weighted Average Shares912.32 K915.81 K1.12 M1.85 M3.98 M4.3 M
Weighted Average Shares Diluted912.32 K915.81 K1.12 M1.85 M3.98 M4.3 M
Income Tax Expense26 K(15 K)(43 K)(126 K)(34 K)(36.68 K)

Kempharm Investors Sentiment

The influence of Kempharm's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Kempharm. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Current Sentiment - KMPH

Kempharm Investor Sentiment

Most of Macroaxis users are now bullish on Kempharm. What is your trading attitude regarding investing in Kempharm? Are you bullish or bearish?
98% Bullish
2% Bearish

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Kempharm using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Stocks Correlation. Note that the Kempharm information on this page should be used as a complementary analysis to other Kempharm's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Complementary Tools for Kempharm Stock analysis

When running Kempharm price analysis, check to measure Kempharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kempharm is operating at the current time. Most of Kempharm's value examination focuses on studying past and present price action to predict the probability of Kempharm's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kempharm's price. Additionally, you may evaluate how the addition of Kempharm to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
The market value of Kempharm is measured differently than its book value, which is the value of Kempharm that is recorded on the company's balance sheet. Investors also form their own opinion of Kempharm's value that differs from its market value or its book value, called intrinsic value, which is Kempharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kempharm's market value can be influenced by many factors that don't directly affect Kempharm underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kempharm's value and its price as these two are different measures arrived at by different means. Investors typically determine Kempharm value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kempharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.